Several studies have indicated that serum or plasma levels of CHI3L1(YKL40) can be used to assess treatment response and prognosis in ovarian cancer patients, in which a higher expression of CHI3L1(YKL40) was associated with poorer outcomes [55,57]. The gene discussed is CHI3L1; the disease is ovarian carcinoma.